Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.218 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities: | ||||||||||||
| Net Income
| -394.582 | -394.582 | 325.312 | 325.312 | -657.909 | -657.909 | -568.043 | -568.043 | -2,350.777 | -2,350.777 | -657.375 | -657.375 |
| Depreciation & Amortization
| 20.503 | 20.503 | 14.115 | 14.115 | 14.251 | 14.251 | 14.084 | 14.084 | 8.648 | 8.648 | 3.597 | 3.597 |
| Deferred Income Tax
| 0 | 0 | -225.717 | -3.531 | -1,670.218 | 647.803 | 349.884 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation
| 14.836 | 14.836 | 11.922 | 11.922 | 15.578 | 15.578 | 31.934 | 31.934 | 45.473 | 45.473 | 17.135 | 17.135 |
| Change In Working Capital
| 38.343 | 38.343 | -18.237 | -18.237 | -219.778 | -219.778 | -234.452 | -234.452 | -965.26 | -965.26 | -10.908 | -10.908 |
| Accounts Receivables
| -11.763 | -11.763 | -0.291 | -0.291 | 1,438.574 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change In Inventory
| 3.753 | 3.753 | -8.101 | -8.101 | -663.381 | -663.381 | -381.817 | -381.817 | -317.518 | -317.518 | -68.36 | -68.36 |
| Change In Accounts Payables
| 0 | 0 | -130.438 | 0 | -160.315 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital
| 46.353 | 46.353 | -9.846 | -9.846 | 443.603 | 443.603 | 147.366 | 147.366 | -647.743 | -647.743 | 57.452 | 57.452 |
| Other Non Cash Items
| 172.158 | 172.158 | -548.308 | -548.308 | 281.82 | 281.82 | 477.111 | 477.111 | 3,030.805 | 3,030.805 | 419.789 | 419.789 |
| Operating Cash Flow
| -148.743 | -148.743 | -215.197 | -215.197 | -566.039 | -566.039 | -279.366 | -279.366 | -231.112 | -231.112 | -227.763 | -227.763 |
| Investing Activities: | ||||||||||||
| Investments In Property Plant And Equipment
| -1.603 | -1.603 | -1.874 | -1.874 | -12.055 | -12.055 | -26.462 | -26.462 | -12.07 | -12.07 | -17.556 | -17.556 |
| Acquisitions Net
| 0 | 0 | 0 | 0 | 2.47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases Of Investments
| 0 | 0 | 0 | 0 | -15.629 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sales Maturities Of Investments
| 0 | 0 | 0 | 0 | -6.214 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activites
| 0.93 | 0.93 | -0.535 | -0.535 | -11.63 | -11.63 | 31.394 | 31.394 | 78.89 | 78.89 | 6.798 | 6.798 |
| Investing Cash Flow
| -0.673 | -0.673 | -2.408 | -2.408 | -23.685 | -23.685 | 4.932 | 4.932 | 66.82 | 66.82 | -10.759 | -10.759 |
| Financing Activities: | ||||||||||||
| Debt Repayment
| 0 | 0 | -120.02 | 0 | -329.703 | 0 | -11.74 | 0 | 0 | 0 | -1.994 | 0 |
| Common Stock Issued
| 0 | 0 | 0.016 | 0 | 502.898 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities
| -110.843 | -110.843 | 39.639 | 39.639 | 248.724 | 248.724 | 4.588 | -7.152 | 792.416 | 792.416 | 738.165 | 736.171 |
| Financing Cash Flow
| -110.843 | -110.843 | 39.639 | 39.639 | 248.724 | 248.724 | -7.152 | -7.152 | 792.416 | 792.416 | 736.171 | 736.171 |
| Other Information: | ||||||||||||
| Effect Of Forex Changes On Cash
| -4.037 | -4.037 | 6.489 | 6.489 | 16.884 | 16.884 | 25.722 | 25.722 | 3.454 | 3.454 | -3.635 | -3.635 |
| Net Change In Cash
| -264.295 | -264.295 | -441.347 | -171.477 | -579.516 | -324.117 | -255.865 | -255.865 | 631.579 | 631.579 | 494.015 | 494.015 |
| Cash At End Of Period
| -264.295 | -264.295 | 1,639.729 | -171.477 | 2,081.077 | 1,931.526 | 2,255.642 | -255.865 | 631.579 | 2,135.792 | 1,504.213 | 494.015 |